Here are five top questions facing emerging biotech companies this year:
Will the IPO market open back up?
The big question facing investors is whether the biotech industry will see the kind of boom it experienced in 2020 and 2021. More than 180 companies went public over that two-year span, compared to just 22 in 2022, according to BioPharma Dive data.
There were several factors for the slowdown: companies that had already gone public struggled to hold onto their value, while clinical and regulatory setbacks combined with macroeconomic forces to sap investor confidence.
